Week in Review: Building a Robust Pipeline for Patients

Week in Review: Building a Robust Pipeline for Patients

05.09.14 | By

Biopharmaceutical innovators work every day to build a robust pipeline and develop new medicines that help patients cope with some of the most debilitating diseases. This week, we released a new Medicines in Development report on mental health disorders that discussed a number of new approaches being pursued in order to treat these conditions. Currently, an estimated 61.5 million Americans suffer from mental illness, or one in every four U.S. adults, and the report highlights more than 100 medications aimed to treat many of these disorders. The medicines in the pipeline provide hope, but the development of new treatments for mental disorders can be difficult.

When examining the progress we’ve made to treat patients with mental illnesses, cancer and other conditions, our the value to patients is apparent. Our own Jennifer Wall addressed this issue in a post this week. She noted that due to the great strides that have been made, diagnoses for some of the nation’s most devastating diseases such as cystic fibrosis and cancers such as leukemia now have treatment options available that were impossible to imagine just a few years ago.

The health of our nation is critically important, and we hope to continue to provide value in the form of new medicines, support and information. Check back with the Catalyst for the most up-to-date information from around the industry and to learn what we are doing to help patient’s live longer, healthier lives.


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context